100 related articles for article (PubMed ID: 10501488)
1. Use of recombinant viruses to assess the pattern of early human immunodeficiency virus breakthrough infection in the presence of stavudine.
Medina DJ; Tung PP; Strair RK
J Gen Virol; 1999 Sep; 80 ( Pt 9)():2361-2367. PubMed ID: 10501488
[TBL] [Abstract][Full Text] [Related]
2. Suppression of replication of multidrug-resistant HIV type 1 variants by combinations of thymidylate synthase inhibitors with zidovudine or stavudine.
Gao WY; Johns DG; Tanaka M; Mitsuya H
Mol Pharmacol; 1999 Mar; 55(3):535-40. PubMed ID: 10051538
[TBL] [Abstract][Full Text] [Related]
3. Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.
Paintsil E; Dutschman GE; Hu R; Grill SP; Lam W; Baba M; Tanaka H; Cheng YC
Antimicrob Agents Chemother; 2007 Nov; 51(11):3870-9. PubMed ID: 17724147
[TBL] [Abstract][Full Text] [Related]
4. Stavudine, nevirapine and ritonavir in stable antiretroviral therapy-experienced children with human immunodeficiency virus infection.
Yogev R; Lee S; Wiznia A; Nachman S; Stanley K; Pelton S; Mofenson L; Fiscus S; Jimenez E; Rathore MH; Smith ME; Song LY; McIntosh K;
Pediatr Infect Dis J; 2002 Feb; 21(2):119-25. PubMed ID: 11840078
[TBL] [Abstract][Full Text] [Related]
5. beta-Estradiol attenuates the anti-HIV-1 efficacy of Stavudine (D4T) in primary PBL.
Zhang M; Huang Q; Huang Y; Wood O; Yuan W; Chancey C; Daniel S; Rios M; Hewlett I; Clouse KA; Dayton AI
Retrovirology; 2008 Sep; 5():82. PubMed ID: 18808673
[TBL] [Abstract][Full Text] [Related]
6. In vivo antagonism with zidovudine plus stavudine combination therapy.
Havlir DV; Tierney C; Friedland GH; Pollard RB; Smeaton L; Sommadossi JP; Fox L; Kessler H; Fife KH; Richman DD
J Infect Dis; 2000 Jul; 182(1):321-5. PubMed ID: 10882616
[TBL] [Abstract][Full Text] [Related]
7. In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication.
Perez-Olmeda M; Garcia-Perez J; Mateos E; Spijkers S; Ayerbe MC; Carcas A; Alcami J
J Med Virol; 2009 Feb; 81(2):211-6. PubMed ID: 19107982
[TBL] [Abstract][Full Text] [Related]
8. Three-drug combinations of emivirine and nucleoside reverse transcriptase inhibitors in vitro: long-term culture of HIV-1-infected cells and breakthrough viruses.
Nitanda T; Wang X; Somekawa K; Yuasa S; Baba M
Antivir Chem Chemother; 2001 May; 12(3):161-7. PubMed ID: 12959324
[TBL] [Abstract][Full Text] [Related]
9. Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens.
Ross L; Scarsella A; Raffanti S; Henry K; Becker S; Fisher R; Liao Q; Hirani A; Graham N; St Clair M; Hernandez J;
AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1107-15. PubMed ID: 11522180
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the phosphorylation of 4'-ethynyl 2',3'-dihydro-3'-deoxythymidine with that of other anti-human immunodeficiency virus thymidine analogs.
Hsu CH; Hu R; Dutschman GE; Yang G; Krishnan P; Tanaka H; Baba M; Cheng YC
Antimicrob Agents Chemother; 2007 May; 51(5):1687-93. PubMed ID: 17353236
[TBL] [Abstract][Full Text] [Related]
11. Effects of aryl substituents on the anti-HIV activity of the arylphosphoramidate derivatives of stavudine.
Uckun FM; Samuel P; Qazi S; Chen C; Pendergrass S; Venkatachalam TK
Antivir Chem Chemother; 2002 May; 13(3):197-203. PubMed ID: 12448692
[TBL] [Abstract][Full Text] [Related]
12. Differential patterns of intracellular metabolism of 2',3'-didehydro-2',3'-dideoxythymidine and 3'-azido-2',3'-dideoxythymidine, two potent anti-human immunodeficiency virus compounds.
Balzarini J; Herdewijn P; De Clercq E
J Biol Chem; 1989 Apr; 264(11):6127-33. PubMed ID: 2539371
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with stavudine (d4T) plus didanosine (ddI) in children with human immunodeficiency virus infection. The Pediatric AIDS Clinical Trials Group 327 Team.
Kline MW; Van Dyke RB; Lindsey JC; Gwynne M; Culnane M; Diaz C; Yogev R; McKinney RE; Abrams EJ; Mofenson LM
Pediatrics; 1999 May; 103(5):e62. PubMed ID: 10224206
[TBL] [Abstract][Full Text] [Related]
14. Novel 4'-substituted stavudine analog with improved anti-human immunodeficiency virus activity and decreased cytotoxicity.
Dutschman GE; Grill SP; Gullen EA; Haraguchi K; Takeda S; Tanaka H; Baba M; Cheng YC
Antimicrob Agents Chemother; 2004 May; 48(5):1640-6. PubMed ID: 15105115
[TBL] [Abstract][Full Text] [Related]
15. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.
Antinori A; Trotta MP; Nasta P; Bini T; Bonora S; Castagna A; Zaccarelli M; Quirino T; Landonio S; Merli S; Tozzi V; Di Perri G; Andreoni M; Perno CF; Carosi G
Antivir Ther; 2006; 11(2):233-43. PubMed ID: 16640104
[TBL] [Abstract][Full Text] [Related]
16. Lack of evidence for in vivo transformation of zidovudine triphosphate to stavudine triphosphate in human immunodeficiency virus-infected patients.
Meléndez M; Blanco R; Delgado W; García R; Santana J; García H; Rosario O; Rodríguez JF
Antimicrob Agents Chemother; 2006 Mar; 50(3):835-40. PubMed ID: 16495240
[TBL] [Abstract][Full Text] [Related]
17. Polyfluoroaromatic stavudine (d4T) ProTides exhibit enhanced anti-HIV activity.
Kandil S; Pannecouque C; Chapman FM; Westwell AD; McGuigan C
Bioorg Med Chem Lett; 2019 Dec; 29(24):126721. PubMed ID: 31679972
[TBL] [Abstract][Full Text] [Related]
18. Thymidine-analog and multi-nucleoside resistance mutations are observed in both zidovudine-naive and zidovudine-experienced subjects with viremia after treatment with stavudine-containing regimens.
Ross L; Henry K; Paar D; Salvato P; Shaefer M; Fisher R; Liao Q; St Clair M
J Hum Virol; 2001; 4(4):217-22. PubMed ID: 11694850
[TBL] [Abstract][Full Text] [Related]
19. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
Izopet J; Bicart-See A; Pasquier C; Sandres K; Bonnet E; Marchou B; Puel J; Massip P
J Med Virol; 1999 Dec; 59(4):507-11. PubMed ID: 10534734
[TBL] [Abstract][Full Text] [Related]
20. Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro.
Hoggard PG; Kewn S; Barry MG; Khoo SH; Back DJ
Antimicrob Agents Chemother; 1997 Jun; 41(6):1231-6. PubMed ID: 9174176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
